Figure 1: Eosinophil infiltration of Lung Transplants.

(A) Graphic representation of a left single lung transplant in the mouse (top). Relative ratio (bottom left) and eosinophil/T cell ratio (bottom right) in resting B6 lungs as well as Balb/c lungs engrafted into B6 mice in the presence or absence of immunosuppression at post-engraftment day 7. (B) Representative Ki-67 expression and viability dye exclusion in eosinophils from lungs in the presence or absence of immunosuppression at post-engraftment day 7. Representative of two separate experiments. (C) Adoptively transferred CD45 congenic eosinophils in the lung or spleen of recipients treated with CSB or not receiving immunosuppression. (D) Tissue infiltration of adoptively transferred eosinophils in the left lung graft of Balb/c to B6 CD45.1 recipients via flow cytometry (left panel) and immunofluorescence (right panel). Intravascular vs. parenchymal identification of SiglecF⁺CD11b^high eosinophils performed by intravascular administration of fluorescently labeled pan-CD45 antibody followed by identification of transferred eosinophils by CD45.2+CD45.1− staining (left panel) or by cell trace violet labeling of eosinophils prior to transfer and visual inspection by fluorescent microscopy (right panel). White arrow points to pulmonary vessel with visible intravascular eosinophils in lungs with (top) or without (bottom) immunosuppression. Representative of two separate experiments. For (C) and (D), eosinophils were injected on post-engraftment day 4 and tissue was collected 18 hours later. CSB=co-stimulatory blockade, CsA/MP=cyclosporine/methylprednisolone. ns=p>0.05; *=p<0.05; **=p<.01; ***=p<.001